[Anticoagulation and anti platelet therapy in patients with chronic kidney disease]

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Patients with chronic kidney disease (CKD) have a high risk of cardiovascular events and atrial fibrillation, necessitating anticoagulation and/or antiplatelet therapy (APT).
• Historically, CKD patients with creatinine clearance below 30 mL/min were excluded from major studies, leading to limited evidence-based guidelines for this population.
• Emerging data are slowly informing updated recommendations for anticoagulation and APT in CKD patients.

Purpose of the Study:

• To review current evidence and provide guidance on the use of anticoagulation and antiplatelet therapy (APT) in patients with chronic kidney disease (CKD).
• To highlight specific recommendations for different stages of CKD, including non-vitamin K dependent oral anticoagulants (NOACs) and vitamin K antagonists (VKAs).
• To address the challenges and considerations for anticoagulating maintenance dialysis patients and the use of APT in moderate to advanced CKD.

Main Methods:

• Review of existing literature and clinical trial data concerning anticoagulation and APT in CKD patients.
• Analysis of guideline recommendations for different CKD stages (1-3, 4, and maintenance dialysis).
• Examination of safety and efficacy data for various anticoagulant and antiplatelet agents in the context of renal impairment.

Main Results:

• In CKD stages 1-3, non-vitamin K dependent oral anticoagulants (NOACs) are preferred over vitamin K antagonists (VKAs).
• Dabigatran should be avoided in CKD stage 4.
• Anticoagulation decisions for maintenance dialysis patients require individual risk assessment; currently, all oral anticoagulants are used off-label in Europe for these patients. Randomized controlled trials are ongoing.
• Antiplatelet therapy (APT) in moderate to advanced CKD carries an increased bleeding risk due to uremic platelet dysfunction, even if not renally eliminated. Dose adjustments for NOACs are crucial when combined with APT.

Conclusions:

• Anticoagulation and APT strategies in CKD patients must be individualized, considering the specific stage of kidney disease and bleeding risk.
• Careful selection of anticoagulants, with preferential use of NOACs in early CKD stages and avoidance of dabigatran in stage 4, is recommended.
• Further research, including ongoing randomized controlled trials, is essential to refine treatment guidelines for anticoagulation and APT in CKD, particularly for maintenance dialysis patients and in combination therapies.